Leukocyte–mimicking Pluronic–lipid nanovesicle hybrids inhibit the growth and metastasis of breast cancer

Chen, Qinyue; Chen, Yi-Ting; Sun, Yahong; He, Wenxiu; Han, Xiaoli; Lu, Enhao; Sha, Xianyi

doi:10.1039/c8nr08936a

Cited by 19 publications

(9 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These observation was in line with previous reports that FA modified in the NLC mediated the cellular uptake of the DDS through the corresponding receptor, which was beneficial for cancer therapy. 32 , 33 …”

Section: Resultsmentioning

confidence: 99%

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

The tumor microenvironment (TME) plays a significant role in weakening the effect of cancer immunotherapy, which calls for the remodeling of TME. Herein, we fabricated a nanostructured lipid carrier (NLC) to codeliver doxorubicin (Dox) and sorafenib (Sfn) as a drug delivery system (NLC/D-S). The Sfn was expected to regulate the TME of esophagus cancer. As a result, the immune response induced by Dox-related immunogenicity cell death could be fully realized. Our results demonstrated that Sfn was able to remodel the TME through downregulation of regulatory T cells (Treg), activation of effector T cells, and relieving of PD-1 expression, which achieved synergistic effect on the inhibition of primary tumor but also subsequent strong immune response on the regeneration of distant tumor.

show abstract

Section: Resultsmentioning

confidence: 99%

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To further elucidate the functional mechanism of the ceRNA network, we established a PPI regulation network, and selecting six hub genes, containing DGAT2, ACSL1, ADIPOQ, LPL, LEP, PCK1. Previous studies have shown that ve genes (DGAT2, ACSL1, ADIPOQ, LPL, and LEP) play important roles in the carcinogenesis of BC [23][24][25][26][27]. However, the relationship between PCK1 and BC has not been investigated, and the correlation between these hub genes and circRNAs in BC has not been reported.…”

Section: Discussionmentioning

confidence: 99%

Construction and Investigation of circRNA-miRNA-mRNA ceRNA regulatory network in breast cancer

Sang

Pan

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Circular RNAs (circRNAs) have drawn lots of attention in tumorigenesis and progression. However, circRNAs as crucial regulators in multitudinous biological processes have not been systematically identified in breast cancer (BC). Our research aims to explore novel circRNAs in BC and their mechanisms of action. Methods The circRNA expression profile data, as well as RNA-sequencing data of BC, were downloaded from public database, respectively. The differentially expressed circRNAs, miRNA, and mRNA were determined via fold change filtering. The competing endogenous RNAs (ceRNAs) network were established on the foundation of the relationship between circular RNAs, miRNAs and mRNAs. GO and KEGG analysis of the overlapped genes were performed to predict the potential functions and mechanisms of circRNAs in BC. The CytoHubba was used to determine the hub genes from the PPI regulatory network. Morever, we further used Kaplan–Meier plotter to perform survival analysis of these hub genes. Real-time PCR was used to validate the expression of the circRNAs in BC tissues. Results A total of seven differential expressed circRNAs were screened. After the predicted target miRNA and DEmiRNA were intersected, four circRNA-miRNA interactions including three circRNAs and four miRNAs were determined. Furthermore, the Venn diagram was used to intersect the predicted target genes and the downregulated differentially expressed genes, and screened 149 overlapped genes. Moreover, we constructed a PPI network, and selecting six hub genes, including DGAT2, ACSL1, ADIPOQ, LPL, LEP, PCK1. Moreover, the survival analysis results revealed that low expression of ADIPOQ, LPL, LEP were obviously correlated with poor prognosis of BC patients. The real-time PCR results demonstrated that, the levels of circ_0028899, circ_0000375, and circ_0000376 were significantly down-regulated in breast cancer tissues. Conclusions Our study constructed and analyzed a circRNA-associated ceRNA regulatory network and discovered that circ_0028899, circ_0000375, and circ_0000376 may function as ceRNAs to serve key roles in BC.

show abstract

“…In another attempt, Chen et al have reported developing a leukocyte-mimetic platform for PTX delivery to breast cancer to inhibit its growth and metastasis. [133] First, they fabricated lipid vesicles based on a mixture of phosphorylcholine lipids and pluronic P123 that contained PTX. Then, the membrane proteins from murine Mϕ cell line J774A.1 were incorporated in the vesicles via extrusion following a thin layer evaporation (TLE) procedure (Figure 14a).…”

Section: Biomedical Application Of Extracted Proteins or Whole Plasmamentioning

confidence: 99%

Chemically Engineered Immune Cell‐Derived Microrobots and Biomimetic Nanoparticles: Emerging Biodiagnostic and Therapeutic Tools

et al. 2021

View full text Add to dashboard Cite

Over the past decades, considerable attention has been dedicated to the exploitation of diverse immune cells as therapeutic and/or diagnostic cell-based microrobots for hard-to-treat disorders. To date, a plethora of therapeutics based on alive immune cells, surface-engineered immune cells, immunocytes' cell membranes, leukocyte-derived extracellular vesicles or exosomes, and artificial immune cells have been investigated and a few have been introduced into the market. These systems take advantage of the unique characteristics and functions of immune cells, including their presence in circulating blood and various tissues, complex crosstalk properties, high affinity to different self and foreign markers, unique potential of their on-demand navigation and activity, production of a variety of chemokines/cytokines, as well as being cytotoxic in particular conditions. Here, the latest progress in the development of engineered therapeutics and diagnostics inspired by immune cells to ameliorate cancer, inflammatory conditions, autoimmune diseases, neurodegenerative disorders, cardiovascular complications, and infectious diseases is reviewed, and finally, the perspective for their clinical application is delineated.

show abstract

Leukocyte–mimicking Pluronic–lipid nanovesicle hybrids inhibit the growth and metastasis of breast cancer

Abstract: We have constructed a novel biomimetic Pluronic-lipid nanovesicle hybrid that mimics leukocytes, to target breast cancer and suppress metastasis.

Cited by 19 publications

References 55 publications

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

Construction and Investigation of circRNA-miRNA-mRNA ceRNA regulatory network in breast cancer

Chemically Engineered Immune Cell‐Derived Microrobots and Biomimetic Nanoparticles: Emerging Biodiagnostic and Therapeutic Tools

Contact Info

Product

Resources

About